NDAORALTABLET
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMVAZ (amlodipine maleate) is an oral calcium channel blocker tablet approved by the FDA for cardiovascular indications. It works by relaxing blood vessels and improving blood flow to treat hypertension and angina. The drug is a small-molecule antihypertensive with a well-established mechanism in the calcium channel blocker class.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), commercial teams face headwinds requiring efficiency and legacy product expertise; expect stable but smaller team sizes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
Started May 2018
36 enrolled
Hypertension
Career Relevance
Working on AMVAZ offers exposure to mature product lifecycle management, generic competition strategy, and market access in a high-volume cardiovascular category. Career growth is tied to operational excellence and managed decline rather than innovation; ideal for professionals seeking stability in a legacy asset environment.
Brand Manager
Worked on AMVAZ at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.